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Stenotrophomonas maltophilia is an emerging nosoco-
mial pathogen in immunocompromised patients [1-3].
Although S. maltophilia exhibits a limited pathogenicity
in immunocompetent hosts, it has been shown to cause
fatal infections in patients with hematologic malignan-
cies. The overall mortality of S. maltophilia bloodstream
infections (BSIs) ranges from 21 to 50%, with the mortality
associated with neutropenia [4-6]. Failure to administra-
tion of early susceptible antibiotics for S. maltophilia BSI
can have clinical implications, as S. maltophilia is nat-
urally resistant to many antimicrobial agents including
carbapenem.
Trimethoprim-sulfamethoxazole (SXT) is the antimicro-
bial agent of choice for the treatment of S. maltophilia in-
fections [7-9]. Levofloxacin is also a viable treatment option
in cases where drug susceptibilities are known [10]. How-
ever, SXT is known to cause adverse events related to bone
marrow suppression, which might delay recovery from neu-
tropenia in patients with hematologic malignancies. Fluoro-
quinolone is commonly used as prophylaxis during stem
cell transplantation (SCT) or chemotherapy. As recent
guidelines and experts have suggested that there are con-
cerns about potential resistance to fluoroquinolone-based
prophylaxis, this prophylactic strategy can lead to a limited
effectiveness of levofloxacin in S. maltophilia infections
[7,11-13]. Data regarding the clinical characteristics and the
treatment outcomes of S. maltophilia BSIs in hematologic
patients who received quinolone prophylaxis remain
insufficient.
As S. maltophilia BSIs are associated with a high mor-
tality rate, and increased resistance to monotherapy,
many groups have suggested the need for combination
antimicrobial therapies [7,14,15]. However, the effective-
ness of combination therapy for S. maltophilia has not
yet been established. Here, we investigated the clinical
characteristics and outcomes related to S. maltophilia
BSIs in patients with hematologic malignancies. Clinical
isolates from these patients were then evaluated for
in vitro susceptibilities with synergistic effects of several
antimicrobial combinations to identify potential thera-
peutic regimens that may improve clinical outcomes.
Methods
Study design and hospital setting
We retrospectively reviewed medical records of all con-
secutive episodes of S. maltophilia BSIs in adult patients
with hematologic malignancies from June 2009 to May
2014 at the Catholic Blood and Marrow Transplantation
Center of Seoul St. Mary’s Hospital.
Clinical data collection
Eligible patients included those with hematologic malig-
nancies older than 19 years of age, with documentedblood cultures positive for S. maltophilia. Clinical data
obtained for each patient included age, sex, underlying
diseases, severity and duration of neutropenia, length of
hospital stay, simplified acute physiology score II (SAPS
II) at the onset of BSI, the presence of central venous
catheters, organisms isolated from blood and the anti-
microbial susceptibility, administered antibiotics, and
survival status at 30 days after the onset of BSI. The
Institutional Review Board of Seoul St. Mary’s Hos-
pital approved the research protocol and waived the
requirement for informed consent (KC13SISI0163).
S. maltophilia 16S rRNA gene analysis & pulsed-field gel
electrophoresis
Available clinical isolates underwent phylogenetic group de-
termination and pulsed-field gel electrophoresis (PFGE).
Clinical isolates were screened using a specific 16S rRNA
gene polymerase chain reaction (PCR) assay, and sequenced
to confirm taxonomic identities. PCR was performed using
primers SM1f (5′-GTTGGGAAAGAAATCCAGC-3′) and
SM4 (5′-TTAAGCTTGCCACGAACAG-3′) as described
previously [16,17]. Sequence analysis of PCR products was
conducted with MEGA version 3.1 using the maximum
likelihood method. AB695350 (S. maltophilia strain 4APB)
was used as a control [18]. S. maltohpilia clinical isolates
were typed using PFGE with Xba I digestion as described
previously [19]. PFGE was performed with a CHEF-DR III
apparatus (Bio-Rad Korea, Seoul, Korea) using 5 to 35 s of
linear ramping at 6 V/cm for 20 h at 14°C. Digital images
were analyzed with Fingerprinting II Informatix software
(Bio-Rad, Hercules, CA, USA) using the Dice coefficient
and UPGMA with a 1% tolerance and 0.5% optimizing set-
ting value. The results were interpreted using the criteria of
Tenover et al. [20].
Antimicrobial susceptibilities and fractional inhibitory
concentrations using a luciferase-based assay
An in vitro susceptibility test was performed for seven
antimicrobial agents (ceftazidime, ciprofloxacin, levo-
floxacin, moxifloxacin, ticarcillin-clavulanic acid [TIM],
tigecycline, and SXT) using the broth microdilution
method according to 2013 Clinical and Laboratory Stan-
dards Institute guidelines [21]. Quality controls were
assessed by using Escherichia coli ATCC 25922 and
Pseudomonas aeruginosa ATCC 27853. TIM was ob-
tained from Biovim Korea Vine & Company (Seoul,
Korea). Tigecycline was obtained from Pfizer Inc. (New
York, NY, USA) via a compound transfer program.
Other antibiotics were obtained from Sigma-Aldrich (St.
Louis, MO, USA). All susceptibility testing was per-
formed using cation-adjusted Mueller-Hinton broth (BD,
Spark, MD, USA). To identify synergistic effects between
SXT and other antibiotics (levofloxacin, moxifloxacin, or
TIM), a checkerboard assay was performed using 96-well
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microdilution endpoint for SXT are difficult to read be-
cause of trailing and bacteriostatic activity of S. maltophi-
lia, a luciferase-based bacterial cell viability assay was used
[22,23]. In this study, a BacTiter-Glo™ microbial cell
viability kit (Promega Corp., Madison, WI, USA) was
used to determine the number of viable bacterial cells
in culture, based on quantification of adenosine tri-
phosphates (ATPs). Graded concentrations of antibi-
otics were mixed to assess synergy test. Each well was
inoculated with 5 × 104 CFU of each isolate in cation-
adjusted Mueller-Hinton broth. The plates were then
incubated for 24 h at 35°C in ambient air. All assays
were performed in triplicate. After 24 h of incubation,
a volume of BacTiter-Glo™ reagent equal to the volume of
the cell culture medium was added to 100 μL of microbial
broth culture in an opaque-walled multi-well plate, ac-
cording to the manufacturer’s instructions. Relative lumi-
nescence units (RLU) were measured using a SpectraMax
L luminescence microplate reader (Molecular Devices,
Sunnyvale, CA, USA). The percentage of RLUs compared
to the antibiotic-free controls (%RLU) was calculated, with
minimal inhibitory concentrations (MICs) defined as
<10%RLU, corresponding to an inhibitory concentration
of 90% (IC90). Total fractional inhibitory concentrations
(FIC) were calculated according to the formula: ΣFIC =
FIC of agent A + FIC of agent B, where FIC of agent A or
B =MIC of agent A or B in combination/MIC of agent A
or B alone. ΣFIC values ≤0.5 indicate synergy, ΣFIC values
of >0.5 and ≤4 indicate indifference, and ΣFIC values >4
indicate antagonism [24].
Definitions
S. maltophilia BSIs were defined as at least one S. malto-
philia-positive blood culture in association with clinical
signs or symptoms indicative of infection [6]. Polymicro-
bial BSIs were defined as the presence of an organism
other than S. maltophilia in the same blood culture. The
source of bacteremia was determined clinically on the
basis of the presence of an active site of infection as de-
termined by chart review or isolation of the organism
from other clinical specimens coincident with the epi-
sode of bacteremia [4]. Neutropenia was defined as an
absolute neutrophil count (ANC) <500/mm3, or <1000/
mm3 with predicted falls to <500/mm3 within 2–3 days.
Severe neutropenia was defined as an ANC <100/mm3
[11,12]. The length of hospitalization before BSI was de-
fined as the number of days from hospital admission to
the development of BSI. Previous antibiotic use was de-
fined as the administration of antibiotics for more than
24 hours within 30 days before the onset of the S. malto-
philia BSI [25]. Mortality was considered attributable to
the S. maltophilia BSI in any of the following cases: (1)
blood cultures positive for S. maltophilia at the time ofdeath; (2) death before the resolution of signs and symp-
toms related to S. maltophilia BSI; (3) death within
7 days of the onset of S. maltophilia BSI and with no
other identifiable cause [26]. Crude mortality was de-
fined as mortality that occurred within a month follow-
ing a BSI episode [27].
Statistical analysis
Differences in continuous variables between the survivors
and non-survivors were analyzed using the Mann–Whitney
U-test. Fisher’s exact test was used to compare categorical
data. We used Cox’s proportional hazard model with for-
ward stepwise selection to identify independent risk factors
for death. Kaplan-Meier survival curves were used to
analyze mortality trends. P value <0.05 was considered sta-
tistically significant. All data were analyzed using SPSS ver.
18.0 (SPSS Korea, Seoul, Korea).
Results
Clinical characteristics of S. maltophilia bloodstream
infection
Among 11,004 of admission episodes, a total of 31 pa-
tients were treated for S. maltophilia BSI. The incidence
rate of S. maltophilia BSI was 0.134 cases per 1,000
patient-days during the entire study period. All patients
had received broad-spectrum antibiotics such as fluoro-
quinolone as prophylaxis, anti-Pseudomonal cephalo-
sporin plus aminoglycoside, or carbapenem as empirical
or targeted therapy due to neutropenic fever within
30 days before the onset of the BSIs. The most com-
monly identified source of BSI was pneumonia (41.9%),
followed by primary BSI (22.6%), catheter-related BSI
(19.4%), skin and soft tissue infection (12.9%), and intra-
abdominal infection (3.2%). In catheter-related S. maltophi-
lia BSIs, Hickman catheters (n = 5) or chemoport (n = 1)
were removed from the patient. In addition, about
one-third of the patients (35.5%) had polymicrobial
BSIs with nosocomial pathogens such as methicillin-
resistant Staphylococcus aureus, methicillin-resistant
coagulase-negative Staphylococcus, P. aeruginosa or
vancomycin-resistant Enterococcus. Although antibiotic
regimens were modified to appropriate targeted therapies
in 26 of 31 patients (83.9%), the overall and attributable
mortality of S. maltophilia BSIs was 64.5% and 38.7%,
respectively.
Clinical characteristics of S. maltophilia BSIs were com-
pared according to overall survival status (Table 1). There
were no differences in age, sex, underlying hematologic
diseases, SAPS II, presence of polymicrobial BSI, or shock
between the two groups. Neutropenia at the onset of BSI
(43% vs. 92%, p =0.038) was significantly associated with
death, in terms of both neutropenia itself and the duration
of neutropenia (median 3 d vs. 40 d, p =0.016). As a
source of BSI, pneumonia (0% vs. 65.0%, p =0.001) was
Table 1 Clinical characteristics of patients with Stenotrophomonas maltophilia bloodstream infections according to the
overall survival status
Variable Survival (n = 11) Death (n = 20) P value
Age 49 (22–65) 48 (18–78) 0.416
Male 6 (54.5%) 12 (60.0%) 0.999
Underlying disease
Myeloid malignancies 6 (54.5%) 15 (75.0%) 0.453
Lymphoid malignancies 3 (27.3%) 3 (15%)
Others 2 (18.2%) 2 (10.0%)
Treatment
Chemotherapy 8 (72.7%) 9 (45.0%) 0.089
Stem cell transplantation 3 (27.3%) 4 (20.0%)
Palliative care 0 (0.0%) 7 (35.0%)
Hospital stay, days 26 (0–48) 23.5 (0–120) 0.119
Duration of neutropeniaa, days 3 (0–36) 40 (1–135) 0.016
Neutropenia at the onset of BSI (<500/mm3) 7 (63.6%) 19 (95.0%) 0.042
Severe neutropenia at the onset of BSI (<100/mm3) 6 (54.5%) 17 (85.0%) 0.095
SAPS II 30 (26–49) 38.5 (23–70) 0.030
Source of infection
Pneumonia 0 (0.0%) 13 (65.0%) 0.001
Catheter 6 (54.5%) 0 (0.0%) 0.001
Primary 3 (27.3%) 4 (20.0%) 0.999
SSTI 1 (9.1%) 3 (15.0%) 0.999
Abdomen 1 (9.1%) 0 (0.0%) 0.355
Polymicrobial BSI 3 (27.3%) 7 (35.0%) 0.999
Shock 2 (18.2%) 12 (60.0%) 0.057
Data are presented as n (%) or median (range).
Abbreviations: BSI, bloodstream infection; SAPS II, Simplified Acute Physiology Score II; SSTI, skin and soft tissue infection.
amissing data (n = 11).
Cho et al. BMC Infectious Diseases  (2015) 15:69 Page 4 of 8more common in non-survivors, while catheter-related in-
fections (54.5% vs. 0%, p =0.001) were more common in
survivors. In patients with combined S. maltophilia pneu-
monia, 64.5% (8 of 13 patients) received mechanical venti-
lation, while 11.1% (2 of 18 patients) with other sources of
BSI received mechanical ventilation.
The results of Cox’s proportional hazard analysis of
factors associated with overall mortality are shown in
Table 2. Severe neutropenia at the onset of BSI (adjusted
hazard ratio [HR] 5.24, 95% Confidence Interval [CI]
1.411-19.493; p =0.013) and shock (adjusted HR 3.15,
95% CI 1.231-8.032; p =0.017) at the onset of BSI, and
pneumonia as a source of BSI (adjusted HR 6.05, 95% CI
2.247-16.291; p <0.001) were associated with an increase
in mortality. Kaplan-Meier survival curves stratified by
source of BSI were shown in Figure 1.
Pulsed-field gel electrophoresis and phylogenetic group
determinations
PFGE typing of available 27 S. maltophilia clinical iso-
lates demonstrated 20 distinguishable banding patternswithout evidence of the clonality. These 20 strains ex-
hibited >99.9% 16S rRNA gene sequence similarity to
the S. maltophilia type strain AB695350.
In vitro susceptibility testing and antimicrobial
combinations
Broth microdilution testing of clinical isolates revealed
88.9% susceptibility to SXT and 44.4% to levofloxacin.
MIC50 and MIC90 values for moxifloxacin and tigecyc-
line showed 1 and 4 mg/L, and 4 and 8 mg/L, respect-
ively (Table 3). Of the 27 clinical isolates, 15 were
chosen for additional synergy testing based upon their
MIC values. The selected isolates were representatives of
the similar MIC patterns to each antmicrobial agent.
Comparison of FIC indices is shown in Table 4. Synergy
between SXT and TIM was found in 9 of 15 strains
(60%) tested, of which the FIC for 50 and 90% of the iso-
lates (FIC50/FIC90) was 0.500/0.750, with a range of
0.254 to 1.500. In the case of SXT plus levofloxacin or
moxifloxacin, FICs ranged from 0.500 to 1.000, and
0.313 to 0.750, respectively. In all of the antimicrobial
Table 2 Factors associated with mortality in patients with Stenotrophomonas maltophilia bloodstream infections
Univariate analysis Multivariate analysis
Variable HR (95% CI) P value Adjusted HR (95% CI) P value
Neutropenia at the onset of BSI (<500/mm3) 5.87 (0.784-44.037) 0.085
Severe neutropenia at the onset of BSI (<100/mm3) 3.47 (1.008-11.954) 0.048 5.24 (1.411-19.493) 0.013
Duration of neutropenia >21 days 3.29 (0.978-11.072) 0.054
Hospital stay >30 days 1.44 (0.586-3.531) 0.428
SAPS II >40 3.14 (1.265-7.783) 0.003
Source of infection
Pneumonia 4.27 (1.687-10.816) 0.002 6.05 (2.247-16.291) <0.001
Catheter 0.03 (0.000-1.817) 0.093
Polymicrobial BSI 1.43 (0.570-3.603) 0.444
Shock 3.09 (1.245-7.666) 0.015 3.15 (1.231-8.032) 0.017
Abbreviations: BSI, bloodstream infection; CI, confidence interval; HR, hazard ratio; SAPS II, Simplified Acute Physiology Score II; SSTI, skin and soft tissue infection
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were under 1.000 without antagonism.
Discussion
In this study, we examined the clinical characteristics
and treatment outcomes in hematologic patients with S.
maltophilia BSIs, as well as the effectiveness of in vitro
antimicrobial combinations against S. maltophilia clinical
isolates. S. maltophilia BSIs still showed high mortality, with
significant correlations seen for severe neutropenia, shock,
and concomitant S. maltophilia pneumonia. Furthermore,Figure 1 Kaplan-Meier curves for survival during episodes of Stenotro
curves for survival stratified by pneumonia as a source of BSI (A), and cathewe discovered that in vitro synergy tests revealed favorable
FIC50 and FIC90 values against S. maltophilia clinical isolates
obtained from hematologic patients.
Our data demonstrated that the previous exposure to
broad spectrum antibiotics was preceded in all of the S.
maltophilia BSIs. Polymicrobial infections were observed
in over one third of patient. Poor prognosis in patients
with combined S. maltophilia pneumonia might be re-
lated to higher rates of mechanical ventilation, when
compared to patients with other sources of BSI. In con-
trast, patients with catheter related BSIs exhibited 100%phomonas maltophilia bloodstream infections. Kaplan–Meier
ter-related BSI (B) (Log-rank test, p <0.001, and 0.003, respectively).
Table 3 In vitro activity of antimicrobial agents against Stenotrophomonas maltophilia isolates
Antimicrobial agent Susceptible isolates (%) MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L)
CAZ 11.11 4 ~≥128 32 ≥128
CIP 0 4 ~≥ 64 32 64
LVX 44.44 0.5 ~ 16 4 8
MXF - 0.125 ~ 8 1 4
SXT 88.89 0.25/4.75 ~ 4/76 0.25/4.75 4/76
TGC - 1 ~ 8 4 8
TIM 40.74 0.5/2 ~ ≥512/2 32/2 128/2
Abbreviations: CAZ, ceftazidime; CIP, ciprofloxacin; LVX, levofloxacin; MXF, moxifloxacin; SXT, trimethoprim-sulfamethoxazole; TGC, tigecycline; TIM, ticarcillin-clavulanic acid
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are likely to be associated with the removal of the cath-
eter. A previous retrospective study found that catheter-
related S. maltophilia BSIs were cured after removal of
the catheter, even without appropriate antibiotics ther-
apy, while a different study observed a significant correl-
ation between mortality and retained catheters [25,28].
However, these studies were limited by the small num-
ber of patients examined, and failed to evaluate other
salvage management such as antibiotics lock therapy in
patients using long-term catheters.
In a worldwide study of the antimicrobial susceptibil-
ities of 1,586 clinical S. maltophilia isolates, SXT and
tigecycline showed susceptibilities of 96.0% and 95.5%,
respectively, followed by levofloxacin with a susceptibil-
ity of 83.4% [29]. A recent study reported no difference
in 30-day mortality between SXT and levofloxacin treat-
ment for S. maltophilia BSIs [10]. However, in vitro suscep-
tibility results from our study also revealed characteristics
indicative of patient therapies. Decreased susceptibility to
levofloxacin was associated with prophylactic fluoroquino-
lone use during the chemotherapy or SCT for hematologic
malignancies. Taken together, levofloxacin may be an ap-
propriate alternative treatment for S. maltophilia infections
though careful patient selection based on the history of pre-
vious fluoroquinolone exposure will be necessary. For SXT,
the susceptibility rate was 88.9% using the broth microdilu-
tion method, compared to 93.9% using an automated sys-
tem (Vitek-2, bioMérieux, Hazelwood, MO, USA). This
difference is likely the result of the inoculum effect and
trailing. The MIC50/90 for moxifloxacin and tigecycline also
showed higher values, and thus needs further evaluation for





SXT plus TIM 0.500 0.750 0.254 to 1.500
SXT plus LVX 0.625 1.000 0.500 to 1.000
SXT plus MXF 0.625 0.625 0.313 to 0.750
Abbreviations: FIC, fractional inhibitory concentration; LVX, levofloxacin; MXF, moxifl
a50% and 90%, ΣFIC for 50% and 90% of the isolates, respectively.In vitro synergy was screened for SXT in combination
with other antimicrobial agents. About 90% of S. malto-
philia isolates were susceptible to SXT, though several
reports of emerging resistance to SXT have been found
[29]. We included TIM as a representative of the beta-
lactam antibiotics, as a result of our in vitro susceptibil-
ity tests. Fluoroquinolone was selected for synergy test
due to its widespread clinical use. Another reason to
choose quinolone as a combination antibiotics was the
possible activity against biofilm formation in device-
related infection or in cystic fibrosis patients [30,31].
Further studies are needed to identify the biofilm activity
of quinolone in hematologic patients. Our study demon-
strated that SXT plus TIM exhibited the highest rates of
synergy among the antibiotic combinations tested. Both
SXT plus levofloxacin and SXT plus moxifloxacin re-
vealed FIC below 1.000 against all of the clinical isolates
tested. Combination therapy may, therefore, represent a
viable option for S. maltophilia BSIs. Further studies
with larger number of patients will be needed to assess
whether the combination therapy has clinical impact in
improving outcomes of S. maltophilia BSI in hematologic
patients.
There are several strengths of this study. First, only
BSI cases were included. In non-bacteremic S. maltophi-
lia infection, it is difficult to distinguish the colonization
from infection, which might influence the outcome ana-
lysis. Second, we calculated the incidence rate of S. mal-
tophilia BSI in hematologic patients. Third, we used a
high-throughput bioluminescence assay to assess the
viability in living organisms, and a luciferase-based assay
for determining the number of viable cells in culture










oxacin; SXT, trimethoprim-sulfamethoxazole; TIM, ticarcillin-clavulanic acid.
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difficulties in reading due to trailing endpoint by converting
MIC to %RLU, equivalent to IC90 values.
Conclusion
In conclusion, S. maltophilia BSIs shows high mortality
in patients with hematologic malignancies. Neutropenia,
shock, and combined S. maltophilia pneumonia are
associated with mortality. Based upon drug susceptibility
testing, the primary treatment of choice in hematologic
patients should be SXT, with combination therapies
including SXT serving as a feasible treatment option
for S. maltophilia BSIs.
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